Latest & greatest articles for copd exacerbations

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd exacerbations or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd exacerbations and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd exacerbations

61. Review: anticholinergics but not B2 agonists reduce exacerbations requiring hospital admission and respiratory deaths in COPD

Review: anticholinergics but not B2 agonists reduce exacerbations requiring hospital admission and respiratory deaths in COPD Review: anticholinergics but not β2 agonists reduce exacerbations requiring hospital admission and respiratory deaths in COPD | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: anticholinergics but not β2 agonists reduce exacerbations requiring hospital admission and respiratory deaths in COPD Article Text Therapeutics Review: anticholinergics but not β 2 agonists reduce exacerbations requiring hospital admission

Evidence-Based Medicine (Requires free registration)2008

62. [Appropriateness use standards for health technologies. Development of explicit criteria for indication of admission in COPD exacerbation]

[Appropriateness use standards for health technologies. Development of explicit criteria for indication of admission in COPD exacerbation] Estandares de uso adecuado de tecnologias sanitarias. Creacion de criterios explicitos de indicacion de ingreso hospitalario en la exacerbacion de EPOC [Appropriateness use standards for health technologies. Development of explicit criteria for indication of admission in COPD exacerbation] Estandares de uso adecuado de tecnologias sanitarias. Creacion de (...) criterios explicitos de indicacion de ingreso hospitalario en la exacerbacion de EPOC [Appropriateness use standards for health technologies. Development of explicit criteria for indication of admission in COPD exacerbation] Quintana JM, Garcia Gutierrez, Aguirre U, Gonzalez Hernandez N, Grupo adecuacion-EPOC, Unidad de investigacion-CIBER Epidemiologia y Salud Publica (CIBERESP), Hospital Galdakao-Usansolo, Bizkaia Citation Quintana JM, Garcia Gutierrez, Aguirre U, Gonzalez Hernandez N, Grupo

Health Technology Assessment (HTA) Database.2008

63. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies

Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies El Moussaoui R, Roede B M, Speelman P, Bresser P, Prins J M, Bossuyt P M CRD summary The authors concluded (...) that short courses of antibiotic therapy (five days or less) are as effective as conventional courses in the treatment of mild to moderate acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis. The review was well conducted and these conclusions appear reliable. Authors' objectives To determine whether a short course of antibiotics (five days or less) is as effective as a conventional longer course in patients with acute exacerbation of chronic obstructive pulmonary disease

DARE.2008

64. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis

Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis Quon B S, Gan W Q, Sin D D CRD summary This review, which assessed the effectiveness of using systemic corticosteroids, antibiotics, and noninvasive positive pressure ventilation (NPPV) for patients with acute (...) exacerbation of chronic obstructive pulmonary disease (COPD), concluded that all three types of treatment can be effective. The authors' conclusions should be interpreted with some caution in light of language and publication bias issues. Authors' objectives To evaluate the effectiveness of systemic corticosteroids, antibiotics and noninvasive positive pressure ventilation (NPPV) for patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Searching The MEDLINE and EMBASE databases

DARE.2008

65. Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD

Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD Article Text Therapeutics Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2008

66. Review: corticosteroids plus long-acting Beta-agonists reduce exacerbations more than long-acting Beta-agonists alone in COPD

Review: corticosteroids plus long-acting Beta-agonists reduce exacerbations more than long-acting Beta-agonists alone in COPD Review: corticosteroids plus long-acting β-agonists reduce exacerbations more than long-acting β-agonists alone in COPD | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: corticosteroids plus long-acting β-agonists reduce exacerbations more than long-acting β-agonists alone in COPD Article Text Therapeutics Review: corticosteroids plus long-acting β-agonists reduce exacerbations more than long-acting β-agonists alone

Evidence-Based Medicine (Requires free registration)2008

67. COPD exacerbations: defining their cause and prevention.

COPD exacerbations: defining their cause and prevention. Exacerbations of chronic obstructive pulmonary disease (COPD) are episodes of worsening of symptoms, leading to substantial morbidity and mortality. COPD exacerbations are associated with increased airway and systemic inflammation and physiological changes, especially the development of hyperinflation. They are triggered mainly by respiratory viruses and bacteria, which infect the lower airway and increase airway inflammation. Some (...) patients are particularly susceptible to exacerbations, and show worse health status and faster disease progression than those who have infrequent exacerbations. Several pharmacological interventions are effective for the reduction of exacerbation frequency and severity in COPD such as inhaled steroids, long-acting bronchodilators, and their combinations. Non-pharmacological therapies such as pulmonary rehabilitation, self-management, and home ventilatory support are becoming increasingly important

Lancet2007

68. Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life

Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life Article Text Therapeutics Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life Free Matthew B Stanbrook , MD, PhD Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2006

69. Patients with acute exacerbations of COPD saw anxiety as a sign, rather than cause, of breathlessness

Patients with acute exacerbations of COPD saw anxiety as a sign, rather than cause, of breathlessness Patients with acute exacerbations of COPD saw anxiety as a sign, rather than cause, of breathlessness | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Patients with acute exacerbations of COPD saw anxiety as a sign, rather than cause, of breathlessness Article Text Qualitative Patients with acute exacerbations of COPD saw anxiety as a sign, rather than cause, of breathlessness Free Paula M Meek , PhD , RN

Evidence-Based Nursing (Requires free registration)2006

70. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD

Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD Salpeter S R, Buckley N S, Salpeter E E CRD summary This review evaluated the safety and efficacy of anticholinergics and β 2 -agonists (...) in chronic obstructive pulmonary disease. The authors concluded that inhaled anticholinergics can significantly reduce the risk of severe exacerbations and respiratory deaths, and that β 2 -agonists are associated with increased respiratory deaths. This was a largely well-conducted review and the authors' conclusions are likely to be reliable. Authors' objectives To evaluate the safety and efficacy of anticholinergics and β 2 -agonists in chronic obstructive pulmonary disease (COPD). Searching MEDLINE, EMBASE and the Cochrane CENTRAL

DARE.2006

71. Secular trends in nosocomial infections and mortality associated with noninvasive ventilation in patients with exacerbation of COPD and pulmonary edema.

Secular trends in nosocomial infections and mortality associated with noninvasive ventilation in patients with exacerbation of COPD and pulmonary edema. CONTEXT: Randomized controlled trials have shown that the use of noninvasive ventilation (NIV) reduces the need for endotracheal intubation and invasive mechanical ventilation and reduces complication rates and mortality in selected groups of patients. But whether these benefits translate to a clinical setting is unclear. OBJECTIVE: To evaluate (...) longitudinally the routine implementation of NIV and its effect on patients admitted to the intensive care unit (ICU) with acute exacerbation of chronic obstructive pulmonary disease (COPD) or severe cardiogenic pulmonary edema (CPE). DESIGN: Retrospective, observational cohort study using prospectively collected data from January 1, 1994, through December 31, 2001. SETTING: A 26-bed medical intensive care unit (ICU) of a French university referral hospital. PARTICIPANTS: A cohort of 479 consecutive patients

JAMA2003

72. Domiciliary non-invasive ventilation for recurrent acidotic exacerbations of COPD: an economic analysis

Domiciliary non-invasive ventilation for recurrent acidotic exacerbations of COPD: an economic analysis Domiciliary non-invasive ventilation for recurrent acidotic exacerbations of COPD: an economic analysis Domiciliary non-invasive ventilation for recurrent acidotic exacerbations of COPD: an economic analysis Tuggey J M, Plant P K, Elliott M W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of domiciliary noninvasive ventilation (NIV) for the management of patients with recurrent admissions because of an acidotic exacerbation of chronic obstructive pulmonary disease (COPD). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients

NHS Economic Evaluation Database.2003

73. Management of acute exacerbations of COPD: a summary and appraisal of published evidence

Management of acute exacerbations of COPD: a summary and appraisal of published evidence Management of acute exacerbations of COPD: a summary and appraisal of published evidence Management of acute exacerbations of COPD: a summary and appraisal of published evidence McCrory DC, Brown C, Gelfand SE, Bach PB Authors' objectives To critically review the available data on the diagnostic evaluation, risk stratification and therapeutic management of patients with acute exacerbations (...) of chronic obstructive pulmonary disease (COPD). Searching MEDLINE (from 1966 to 2000), EMBASE (from 1974 to 2000), HealthSTAR (from 1975 to 2000) and the Cochrane Controlled Trials Register (Issue 1, 2000) were searched. Several search strategies that included the terms 'COPD' and 'acute exacerbations' were employed. The reference lists of retrieved articles were also checked. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were used, except for some treatment and diagnostic

DARE.2001

74. What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD?

What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD? What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD? What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD? Hender K Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Hender K. What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD? Centre for Clinical Effectiveness (CCE). Evidence Centre Evidence Report. 2000 Authors' objectives This aim of this report was to assess the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD. Authors' conclusions - One systematic review was identified that met

Health Technology Assessment (HTA) Database.2000